Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02182206
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 18, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))

Condition or disease Intervention/treatment Phase
Tumors Drug: BIBF 1120 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
Study Start Date : June 2003
Actual Primary Completion Date : June 2005

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIBF 1120 Drug: BIBF 1120



Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of BIBF 1120 [ Time Frame: Up to 7 months ]
  2. Incidence and intensity of Adverse Events according to common toxicity criteria (CTC) associated with increasing doses of BIBF 1120 [ Time Frame: Up to 7 months ]

Secondary Outcome Measures :
  1. Transfer constant (Ktrans) [ Time Frame: Screening, day 2, 28 and 56 ]
  2. Extravascular-extracellular leakage volume (ve) [ Time Frame: Screening, day 2, 28 and 56 ]
  3. Area under the gadolinium concentration time curve [0-60 seconds] (AUC[Gd]) [ Time Frame: Screening, day 2, 28 and 56 ]
  4. Relative blood volume (rBV) [ Time Frame: Screening, day 2, 28 and 56 ]
  5. Mean transit time (MTT) [ Time Frame: Screening, day 2, 28 and 56 ]
  6. Relative blood flow (rBF) [ Time Frame: Screening, day 2, 28 and 56 ]
  7. Volume of tumour showing contrast uptake [ Time Frame: Screening, day 2, 28 and 56 ]
  8. Volume of tumour showing no contrast uptake [ Time Frame: Screening, day 2, 28 and 56 ]
  9. Restricted diffusion [ Time Frame: Screening, day 2, 28 and 56 ]
  10. Vessel size index [ Time Frame: Screening, day 2, 28 and 56 ]
  11. Change in Eastern Cooperative Oncology Group (ECOG) performance score [ Time Frame: Baseline, up to 7 months ]
  12. Objective tumour responses according to the response evaluation criteria in solid tumour (RECIST) [ Time Frame: Baseline, up to 7 months ]
  13. Area under the plasma concentration-time curve following the first dose of uniform intervals τ over the time interval from zero to 24 hours (AUCτ,1) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  14. Area under the plasma concentration-time curve over the time interval from zero to the time of the last quantifiable drug concentration (AUC0-tz) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  15. Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-∞) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  16. Maximum measured plasma concentration following the first dose of uniform intervals τ (Cmax,1) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  17. Time from dosing to the maximum plasma concentration following the first dose of uniform intervals τ (tmax,1) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  18. Terminal half-life (t1/2) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  19. Mean residence time (MRTpo) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  20. Apparent clearance (CL/F) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  21. Apparent volume of distribution during the terminal phase (Vz/F) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  22. Area under the plasma concentration-time curve over the dosing interval τ (24 h) at steady state (AUCτ,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  23. Predose plasma concentration at steady state immediately before dosing (Cpre,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  24. Maximum plasma concentration at steady state over the dosing interval τ (Cmax,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  25. Time from dosing to the maximum plasma concentration at steady state over the dosing interval τ (tmax,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  26. Terminal half-life at steady state (t1/2,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  27. Apparent clearance at steady state (CL/F,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  28. Mean residence time at steady state (MRTpo,ss), [ Time Frame: up to 24 hours after drug administration on day 27 ]
  29. Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  30. Accumulation ratio (RA) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  31. Minimum measured plasma concentration following the first dose of uniform intervals τ (Cmin,1) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  32. Time from first dosing to the minimum plasma concentration over the dosing interval τ (tmin,1) [ Time Frame: up to 24 hours after the first dose on day 1 ]
  33. Minimum measured plasma concentration at steady state over the dosing interval τ (Cmin,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  34. Time from last dosing to the minimum plasma concentration at steady state over the dosing interval τ (tmin,ss) [ Time Frame: up to 24 hours after drug administration on day 27 ]
  35. Predose concentration of the 15th dose over the dosing interval τ (Cpre,15) [ Time Frame: pre-dose on day 15 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who were not amenable to established forms of treatment
  • Measurable tumour deposits by one or more techniques (X-ray), Computed Tomography (CT), Magnetic Resonance Imaging (MRI))
  • At least one tumour lesion considered suitable for DCE-MRI as determined by discussion with centre radiologist. This lesion must not have been previously irradiated
  • Age 18 years or older
  • Life expectancy of at least three months
  • Written informed consent given consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1
  • Patients completely recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies

Exclusion Criteria:

  • Surgical procedures within four weeks of initiating treatment with the study drug, active ulcers, or injuries with incomplete wound healing
  • Active infectious disease
  • Uncontrolled, severe hypertension (diastolic BP (Blood Pressure) >100 mmHg, Systolic BP>180 mmHg)
  • Gastrointestinal disorders that might have interfered with the resorption of the study drug
  • Serious illness or concomitant non-oncological disease considered by the investigator to have been incompatible with the protocol
  • Brain metastases requiring therapy
  • Absolute neutrophil count less than 1500/mm3
  • Platelet count less than 100 000/mm3
  • Bilirubin greater than 1.5 mg/dl (>26 μmol/L, System International (SI) unit equivalent)
  • Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
  • Serum creatinine greater than 1.5 mg/dl (>132μmol/L, SI unit equivalent)
  • Women and men who were sexually active and unwilling to use a medically acceptable method of contraception
  • Pregnancy or breastfeeding
  • Treatment with other investigational drugs; chemotherapy or hormone therapy (excluding Lutenizing Hormone Releasing Hormone (LHRH) agonists or bisphosphonates provided the lesion for MR (magnetic resonance) imaging did not arise from bone) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study
  • Patients unable to comply with the protocol
  • Active alcohol or drug abuse
  • History of autoimmune disease
  • History of allergy to gadolinium or other intravenous (IV) contrast agent, indwelling medical devices or any other condition that would preclude MR scanning
  • Patients requiring the ongoing use of dexamethasone, anti-histamines, anti-hypertensives or medications for the control of cardiac failure such as diuretics, where there was likely to be a need for alteration of dose during the study period. Dose adjustment of such medications may have independently altered vascular permeability or blood flow

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02182206    
Other Study ID Numbers: 1199.3
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 18, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Nintedanib
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action